NA
RXRX icon

NewEdge Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

NewEdge Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.6K Sell
29,513
-4,244
-13% -$16.4K ﹤0.01% 2785
2025
Q4 		$138K Buy
33,757
+20,226
+149% +$100K ﹤0.01% 2682
2025
Q3 		$66K Buy
13,531
+2,470
+22% +$13K ﹤0.01% 2742
2025
Q2 		$56K Buy
11,061
+2,428
+28% +$11.9K ﹤0.01% 2630
2025
Q1 		$45.7K Buy
8,633
+786
+10% +$5.73K ﹤0.01% 2579
2024
Q4 		$53K Buy
7,847
+2,387
+44% +$16K ﹤0.01% 2509
2024
Q3 		$36K Buy
5,460
+2,860
+110% +$20.5K ﹤0.01% 2535
2024
Q2 		$19.5K Buy
2,600
+500
+24% +$4.36K ﹤0.01% 2635
2024
Q1 		$20.9K Hold
2,100
– – ﹤0.01% 2614
2023
Q4 		$20.7K Buy
2,100
+464
+28% +$3.31K ﹤0.01% 2563
2023
Q3 		$12.5K Buy
+1,636
New +$16.3K ﹤0.01% 2502

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NewEdge Advisors's RXRX Position: Q1 2026 in Review

NewEdge Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 13% in Q1 2026, selling an estimated $16.4K and leaving 29,513 shares worth $90.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2785.

NewEdge Advisors first reported a position in RXRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $138K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • NewEdge Advisors held 29,513 shares of Recursion Pharmaceuticals worth $90.6K as of Q1 2026.
  • NewEdge Advisors sold 4,244 Recursion Pharmaceuticals shares in Q1 2026, an estimated $16.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2785 holding.
  • NewEdge Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • NewEdge Advisors's Recursion Pharmaceuticals position peaked at $138K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.